CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) wi.

Business Wire • Aug 3, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jul 30, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

GlobeNewsWire • Jul 21, 2026

Omeros Corporation Investigated by the Portnoy Law Firm

LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation , (“ Omeros " or the "Company") ( NASDAQ : OMER ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

GlobeNewsWire • Jul 13, 2026

OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

LOS ANGELES, July 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or “the Company”) (NASDAQ: OMER) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

GlobeNewsWire • Jul 8, 2026

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

Heartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data for heart disease. Omeros is launching its first commercial product, Yartemlea, while maintaining a pipeline focused on rare diseases.

The Motley Fool • Jul 8, 2026

Omeros stock crashes on regulatory setback: buy the dip?

Omeros Corp (OMER) stock is tumbling on Friday morning following a major regulatory setback in Europe that has caught investors off guard. Investors are bailing on OMER mostly because the European Medicines Agency's (EMA) expert panel has rejected its primary commercial asset.

Invezz • Jun 26, 2026

FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide

The European Medicines Agency's Human Medicines Committee (CHMP) on Friday issued a negative opinion for Omeros Corp.'s (NASDAQ:OMER) narsoplimab.

Benzinga • Jun 26, 2026

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with.

Business Wire • Jun 26, 2026

NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?

NovoCure maintains a commercialized revenue base through its proprietary Tumor Treating Fields oncology platform. Omeros is focused on high-potential therapies for rare diseases and maintains a significant partnership with a global pharmaceutical giant.

The Motley Fool • Jun 22, 2026